Cambridge Epigenetix strengthens management team
Cambridge, UK, June 13, 2017: Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, has today announced that it has made a number of advisory and staff appointments, strengthening the team as the company transitions towards becoming an integrated commercial epigenetic biomarker discovery venture. The appointments are:
Vitali Proutski, MD, DPhil (Oxon), VP of Bioinformatics has worked within both biopharma and CRO sectors. He brings significant expertise in discovering and developing reliable, clinically-relevant biomarkers and establishing robust biomarker discovery methodologies. Vitali was previously Co-Founder and CEO of National Bioservice LLC, and has held senior roles at AstraZeneca, Almac Diagnostics and Organon Research.
Suman Shirodkar, MBBS., PhD., Strategic Clinical Advisor has senior leadership experience in all stages of product commercialisation, spanning clinical development, new product planning and launches and management of in line marketed products. She has worked on blockbuster products including Lipitor, Diovan, Gleevec and Jakavi. She also has management consulting experience with McKinsey & Company.
Aisling O'Reilly, PhD., QA and Systems Advisor has 16 years’ experience as a quality assurance and regulatory consultant, particularly focused on implementing Quality Management Systems in start-up organisations and engaging with regulatory agencies.
Dr Jason Mellad, CEO at Cambridge Epigenetix, commented: “These appointments are part of our strategy to strengthen our position as an integrated commercial epigenetic biomarker discovery venture. With their experience of working with pharma companies and commercialising diagnostic assays, we will draw on the team’s extensive network to raise awareness of the technologies and capabilities we have developed to enable our partners to unlock the tremendous potential of epigenetic analysis and biomarker discovery.”
Notes to Editors
Phone: +44 (0)7811 996 942
About Cambridge Epigenetix
Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilises innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq). This technology enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com